Quick Answer
Vaxart, Inc. reported Total Revenue of $237.26 million for fiscal year 2025.
Vaxart, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $237.26M +726.7% |
$28.70M +288.9% |
$7.38M | — | — | — |
| Net Income | $16.33M +124.4% |
-$66.95M +18.8% |
-$82.47M +23.5% |
-$107.76M -52.9% |
-$70.47M -118.7% |
-$32.22M -72.8% |
| Diluted EPS | $0.07 +121.2% |
-$0.33 | — | — | — | — |
| Total Assets | $186.08M +11.8% |
$166.39M +81.2% |
$91.83M -40.3% |
$153.85M -30.4% |
$221.17M +45.0% |
$152.58M +312.0% |
| Cash and Equivalents | — | — | $34.76M -21.0% |
$44.01M -69.4% |
$143.75M | — |
| Stockholders Equity | $87.80M +49.0% |
$58.92M +1.9% |
$57.80M -47.7% |
$110.60M -41.0% |
$187.53M +52.0% |
$123.40M +852.8% |
| R&D Expense | $201.58M +171.6% |
$74.21M +8.9% |
$68.14M -15.9% |
$81.05M +66.3% |
$48.75M +145.4% |
$19.86M +36.6% |
| Operating Income | $18.07M +127.3% |
-$66.29M +20.5% |
-$83.35M +27.3% |
-$114.59M -57.5% |
-$72.75M -141.1% |
-$30.17M -91.1% |
| Shares Outstanding | 240.49M +5.6% |
227.77M +48.4% |
153.45M +14.3% |
134.20M +6.9% |
125.59M +13.9% |
110.27M +128.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $72.41M | +1367.9% | +82.3% |
| Net Income | September 30, 2025 | -$8.14M | +42.2% | +45.7% |
| Diluted EPS | March 31, 2019 | -$0.18 | -136.7% | -136.7% |
| Total Assets | September 30, 2025 | $208.99M | +25.4% | +27.4% |
| Cash and Equivalents | September 30, 2024 | $22.04M | -33.5% | -17.6% |
| Stockholders Equity | September 30, 2025 | $26.76M | -60.9% | -18.6% |
| R&D Expense | September 30, 2025 | $75.95M | +404.1% | +52.7% |
| Operating Income | September 30, 2025 | -$7.81M | +46.0% | +46.5% |
| Shares Outstanding | September 30, 2025 | 228.96M | +0.7% | +0.0% |
- Vaxart, Inc. reported Total Revenue of $237.26 million for fiscal year 2025.
- Vaxart, Inc. showed an increase of +726.7% in Total Revenue compared to the prior fiscal year.
- Vaxart, Inc. reported Net Income of $16.33 million for fiscal year 2025.
- Vaxart, Inc. showed an increase of +124.4% in Net Income compared to the prior fiscal year.
- Vaxart, Inc. reported Diluted EPS of $0.07 per share for fiscal year 2025.
- Vaxart, Inc. showed an increase of +121.2% in Diluted EPS compared to the prior fiscal year.
- Vaxart, Inc. reported Total Assets of $186.08 million for fiscal year 2025.
- Vaxart, Inc. showed an increase of +11.8% in Total Assets compared to the prior fiscal year.
- Vaxart, Inc. reported Cash and Equivalents of $34.76 million for fiscal year 2023.
- Vaxart, Inc. showed a decrease of -21.0% in Cash and Equivalents compared to the prior fiscal year.
- Vaxart, Inc. reported Stockholders Equity of $87.80 million for fiscal year 2025.
- Vaxart, Inc. showed an increase of +49.0% in Stockholders Equity compared to the prior fiscal year.
- Vaxart, Inc. reported R&D Expense of $201.58 million for fiscal year 2025.
- Vaxart, Inc. showed an increase of +171.6% in R&D Expense compared to the prior fiscal year.
- Vaxart, Inc. reported Operating Income of $18.07 million for fiscal year 2025.
- Vaxart, Inc. showed an increase of +127.3% in Operating Income compared to the prior fiscal year.
- Vaxart, Inc. reported Shares Outstanding of 240.49 million shares for fiscal year 2025.
- Vaxart, Inc. showed an increase of +5.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: